Freestone Capital Holdings, LLC Genmab A/S Transaction History

Freestone Capital Holdings, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $4,514 - $6,482	-146 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$33.66 - $40.76 $4,207 - $5,095	-125 Reduced 46.13%	146 $5.94 Million
Q3 2020 Nov 06, 2020	SELL	$33.07 - $38.68 $212,011 - $247,977	-6,411 Reduced 95.94%	271 $9,000
Q2 2020 Aug 04, 2020	SELL	$20.05 - $33.89 $309,431 - $523,024	-15,433 Reduced 69.79%	6,682 $226,000
Q1 2020 May 12, 2020	BUY	$17.15 - $25.22 $66,610 - $97,954	3,884 Added 21.3%	22,115 $469,000
Q4 2019 Feb 04, 2020	BUY	$18.88 - $24.14 $39,515 - $50,525	2,093 Added 12.97%	18,231 $407,000
Q3 2019 Nov 07, 2019	BUY	$18.0 - $21.38 $290,484 - $345,030	16,138 New	16,138 $327,000

238

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.4B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Freestone Capital Holdings, LLC, based on Form 13F filings with the SEC.

Stay updated on Freestone Capital Holdings, LLC with notifications on news.